KYTH Insider Trading Activity and SEC Form 4 Filings
KYTH insider trading summary
No open-market insider purchases or sales of Kythera Biopharmaceuticals Inc (KYTH) have been reported on SEC Form 4 in the past 12 months.
Latest KYTH insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 24, 2015 | John W Smither | Chief Financial Officer | Sell | $1.0M (13,763 @ $74.90) |
| Sep 24, 2015 | Frederick Beddingfield III | Chief Medical Officer | Sell | $8.3M (110,638 @ $74.91) |
| Sep 24, 2015 | John W Smither | Chief Financial Officer | Sell | $985K (13,154 @ $74.90) |
| Sep 23, 2015 | Elisabeth Sandoval | Chief Commercial Officer | Sell | $2.0M (26,800 @ $74.90) |
| Sep 23, 2015 | Elisabeth Sandoval | Chief Commercial Officer | Sell | $891K (11,892 @ $74.90) |
| Sep 23, 2015 | John W Smither | Chief Financial Officer | Sell | $1.0M (13,646 @ $74.90) |
| Sep 23, 2015 | Keith Klein | General Counsel | Sell | $835K (11,150 @ $74.90) |
| Sep 23, 2015 | Keith Klein | General Counsel | Sell | $1.1M (14,203 @ $74.90) |
| Sep 23, 2015 | Keith Klein | General Counsel | Sell | $2.0M (26,800 @ $74.90) |
| Sep 23, 2015 | John W Smither | Chief Financial Officer | Sell | $994K (13,272 @ $74.90) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.